Skip to main content

Make Biotech Cash Considerations With SBIO

In financial markets, it’s often said that cash is king. That’s something to remember when it comes to the biotechnology universe due to the cost-intensive nature of developing new drugs and therapies. As a result, analysts and investors often monitor cash burn rates among biotech companies because...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.